REG - Oxford Biomedica PLC - OXB Appoints Non-Executive Director

Oxford BioMedicaAnnouncement

25/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240725:nRSY8078Xa&default-theme=true

RNS Number : 8078X  Oxford Biomedica PLC  25 July 2024

 

Oxford Biomedica Appoints Laurence Espinasse as Non-Executive Director

 

 

Oxford, UK - 25 July 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica", "OXB" or "the Company"), a quality and innovation-led cell and
gene therapy CDMO, today announces the appointment of Laurence Espinasse as a
Non-Executive Director, effective as of 24 July 2024.

 

Ms. Espinasse brings more than two decades of experience across the legal and
healthcare sectors and since 2021 has served as the General Counsel and
Compliance Officer at Institut Mérieux SA ("Institut Mérieux"). Following
the acquisition
(https://www.londonstockexchange.com/news-article/OXB/completion-of-transaction/16308118)
of ABL Europe (since renamed Oxford Biomedica (France)) in January 2024,
Institut Mérieux is now a major shareholder in Oxford Biomedica, owning more
than 10 percent of the Company's ordinary shares.

 

Prior to her current role at Institut Mérieux, Ms. Espinasse was a Partner
and Head of the Business Law Department at MDL Société d'Avocats. Before
that, she practiced business law at EY. She obtained her professional lawyer's
certificate from the École des Avocats Centre Sud in Montpellier, France.

 

Dr. Roch Doliveux, Chair of Oxford Biomedica, commented: "On behalf of the
Board, I am delighted to welcome Laurence Espinasse as Non-Executive Director.
Her vast legal experience will be a strong asset for the Company as we look to
build on significant commercial momentum and capitalise on the fast-growing
cell and gene therapy sector. We look forward to her support and advice in
driving OXB's continued success."

Laurence Espinasse, incoming Board Member at Oxford Biomedica,
added: "Following the acquisition of ABL Europe, I am honoured to be joining
Oxford Biomedica's Board of Directors. Institut Mérieux's significant
investment reflects our confidence in Oxford Biomedica's potential. I look
forward to working closely with the Board to drive the next phase of growth as
a world-leading cell and gene therapy CDMO."

Relevant disclosures

 

Ms. Espinasse previously served as a director at Transgene SA, from May 2022
to May 2023. There are no additional disclosures required to be made in
accordance with LR 9.6.13R.

-Ends-

 

Enquiries:

Oxford Biomedica plc:

Sophia Bolhassan, Head of Investor Relations - T: +44 (0) 1865 509 737 / E:
ir@oxb.com

ICR Consilium:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract
development and manufacturing organisation (CDMO) in cell and gene therapy
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25
years of experience in viral vectors; the driving force behind the majority of
cell and gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus, and other viral vector types. Oxford Biomedica's
world-class capabilities span from early-stage development to
commercialisation. These capabilities are supported by robust
quality-assurance systems, analytical methods and depth of regulatory
expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon
and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com
(https://www.oxb.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/)  and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEELBLZDLEBBL